Gavocabtagene autoleucel — Investigational Agent
TCR Therapy · Phase 1/2 · TCR2 Therapeutics / Adaptimmune
Mechanism of Action
Gavo-cel is an autologous T-cell therapy engineered with a T-cell receptor fusion construct targeting mesothelin, redirecting patient T cells to kill mesothelin-expressing tumor cells.
Investigational Indications
- Mesothelin-expressing ovarian cancer
- Malignant mesothelioma
- Mesothelin-expressing solid tumors